Akebia Therapeutics, Inc. (AKBA) At $10.70 Forms Bottom; DOSHISHA CO LTD ORDINARY SHARES JAPAN (DSHIF) Shorts Raised By 108.33%

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Logo

Akebia Therapeutics, Inc. (AKBA) formed multiple bottom with $10.17 target or 5.00% below today’s $10.70 share price. Akebia Therapeutics, Inc. (AKBA) has $608.65M valuation. The stock decreased 0.47% or $0.05 during the last trading session, reaching $10.7. About 342,536 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has declined 25.63% since June 26, 2017 and is downtrending. It has underperformed by 38.20% the S&P500. Some Historical AKBA News: 30/05/2018 – Akebia Therapeutics Closes Below 50-Day Average: Technicals; 12/03/2018 – AKEBIA THERAPEUTICS FILES MIXED SECURITIES SHELF; 15/05/2018 – Akebia Therapeutics at UBS Global Healthcare Conference May 22; 12/03/2018 – AKEBIA SEES VADADUSTAT TOP-LINE PHASE 3 DATA NEXT YEAR; 22/03/2018 – Akebia Therapeutics Announces Proposed Public Offering of Common Stk; 21/05/2018 – Akebia Therapeutics Presenting at UBS Conference Tomorrow; 22/03/2018 – AKEBIA THERAPEUTICS TO OFFER ABOUT $85M OF SHRS; 22/03/2018 – AKEBIA – INTENDS TO USE NET PROCEEDS FROM OFFERING FOR CONTINUED CLINICAL DEVELOPMENT, OPTIMIZATION OF VADADUSTAT PROGRAM; 12/03/2018 Akebia Therapeutics 4Q Rev $87.3M; 23/04/2018 – DJ Akebia Therapeutics Inc, Inst Holders, 1Q 2018 (AKBA)

DOSHISHA CO LTD ORDINARY SHARES JAPAN (OTCMKTS:DSHIF) had an increase of 108.33% in short interest. DSHIF’s SI was 5,000 shares in June as released by FINRA. Its up 108.33% from 2,400 shares previously. The SI to DOSHISHA CO LTD ORDINARY SHARES JAPAN’s float is 0.03%. It closed at $22.8 lastly. It is down 0.00% since June 26, 2017 and is . It has underperformed by 12.57% the S&P500.

Among 11 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Akebia Therapeutics Inc has $30.0 highest and $10 lowest target. $21.90’s average target is 104.67% above currents $10.7 stock price. Akebia Therapeutics Inc had 25 analyst reports since August 13, 2015 according to SRatingsIntel. Brean Capital initiated Akebia Therapeutics, Inc. (NASDAQ:AKBA) on Thursday, September 29 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, March 15 report. H.C. Wainwright maintained Akebia Therapeutics, Inc. (NASDAQ:AKBA) rating on Monday, July 10. H.C. Wainwright has “Buy” rating and $2400 target. Morgan Stanley upgraded the shares of AKBA in report on Wednesday, September 9 to “Overweight” rating. BTIG Research initiated the shares of AKBA in report on Thursday, December 7 with “Buy” rating. The rating was maintained by Aegis Capital with “Buy” on Friday, June 30. H.C. Wainwright maintained the shares of AKBA in report on Wednesday, August 9 with “Buy” rating. JMP Securities maintained Akebia Therapeutics, Inc. (NASDAQ:AKBA) on Wednesday, December 21 with “Mkt Outperform” rating. The stock has “Buy” rating by H.C. Wainwright on Monday, December 7. The firm earned “Buy” rating on Tuesday, December 15 by H.C. Wainwright.

Investors sentiment increased to 1.9 in Q1 2018. Its up 0.27, from 1.63 in 2017Q4. It is positive, as 14 investors sold Akebia Therapeutics, Inc. shares while 28 reduced holdings. 37 funds opened positions while 43 raised stakes. 39.14 million shares or 29.30% more from 30.27 million shares in 2017Q4 were reported. 1,610 were reported by Sei Invests. Legal General Public Lc reported 8,259 shares stake. Wells Fargo And Co Mn holds 114,178 shares or 0% of its portfolio. Dekabank Deutsche Girozentrale holds 0% or 20,600 shares. Prelude Mgmt Limited Liability Co invested 0.01% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Mutual Of America Cap Mgmt, New York-based fund reported 133,929 shares. Plante Moran Financial Advisors Limited Liability Co owns 0.01% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 1,500 shares. Metropolitan Life Ins Communication New York holds 0% or 14,181 shares in its portfolio. Marshall Wace Ltd Liability Partnership owns 234,769 shares. Artal stated it has 0.06% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Moreover, Goldman Sachs Group Inc has 0% invested in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 781,457 shares. Assetmark stated it has 55 shares or 0% of all its holdings. Wellington Mgmt Gp Limited Liability Partnership holds 0% or 643,084 shares. State Street holds 1.50 million shares. Citigroup stated it has 35,859 shares.

Since February 15, 2018, it had 0 insider purchases, and 1 insider sale for $14,620 activity. Nash Duane had sold 1,000 shares worth $14,620.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Ratings Chart